• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CMCT Announces 30,821-Square-Foot Lease to Boston Scientific Corporation at Penn Field, a 228,000-Square-Foot Creative Office Campus in Austin

    8/5/25 8:00:00 AM ET
    $BSX
    $CMCT
    Medical/Dental Instruments
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $BSX alert in real time by email

    Transaction Brings Property to 93% Leased

    Creative Media and Community Trust Corporation ("CMCT") (NASDAQ:CMCT) announced today that it has executed an approximately 11-year lease with Boston Scientific Corporation (NYSE:BSX) for an entire 30,821-square-foot, one-story building at its Penn Field Campus located at 3601 S. Congress Avenue in Austin, Texas.

    Boston Scientific is a global medical technology leader that provides a broad range of high-performance solutions that address unmet patient needs and reduces the cost of healthcare. The company's devices and therapies help physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

    Penn Field, an approximately 228,000-square-foot, 16-acre, mixed-use property located in Austin's "SoCo" Business District, was originally developed in 1918 as an air base for the U.S. Army. The industrial buildings of post-World War I design have been transformed over time into what is today, a lushly landscaped campus with meandering pathways shaded by mature trees. The property has a diverse tenant base including technology, media, and entertainment companies.

    AQUILA Commercial, in partnership with CIM Group's in-house leasing team, represented CMCT in the transaction. Penn Field is now 93% leased as of August 2025.

    ABOUT CMCT

    Creative Media & Community Trust Corporation ("CMCT") is a real estate investment trust that owns, operates and develops premier multifamily and creative office assets in vibrant communities throughout the United States. CMCT is a leader in creative office, acquiring and developing properties catering to rapidly growing industries such as technology, media and entertainment. CMCT applies the expertise of CIM Group, L.P. to the acquisition, development, and operation of top-tier multifamily properties situated in dynamic markets with similar business and employment characteristics to its creative office investments. CMCT also owns one hotel in Northern California and a lending platform that originates loans under the Small Business Administration's 7(a) loan program. CMCT is operated by affiliates of CIM Group, L.P., a vertically integrated owner and operator of real assets with multi-disciplinary expertise and in-house research, acquisition, credit analysis, development, finance, leasing, and onsite property management capabilities. (www.creativemediacommunity.com)

    Forward Looking Statements

    This press release contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are intended to be covered by the safe harbors created thereby. These statements include the plans and objectives of management for future operations, including plans and objectives relating to future growth of CMCT's business and availability of funds. Such forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "project," "target," "expect," "intend," "might," "believe," "anticipate," "estimate," "could," "would," "continue," "pursue," "potential," "forecast," "seek," "plan," or "should," or "goal" or the negative thereof or other variations or similar words or phrases. Such forward-looking statements also include, among others, statements about CMCT's plans and objectives relating to future growth and outlook. Such forward-looking statements are based on particular assumptions that management of CMCT has made in light of its experience, as well as its perception of expected future developments and other factors that it believes are appropriate under the circumstances. Forward-looking statements are necessarily estimates reflecting the judgment of CMCT's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include those associated with (i) the timing, form, and operational effects of CMCT's development activities, (ii) the ability of CMCT to raise in place rents to existing market rents and to maintain or increase occupancy levels, (iii) fluctuations in market rents, (iv) the effects of inflation and continuing higher interest rates on the operations and profitability of CMCT and (v) general economic, market and other conditions. Additional important factors that could cause CMCT's actual results to differ materially from CMCT's expectations are discussed in "Item 1A—Risk Factors" in CMCT's Annual Report on Form 10-K for the year ended December 31, 2024 and in Part II, Item 1A of CMCT's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission from time to time. The forward-looking statements included herein are based on current expectations and there can be no assurance that these expectations will be attained. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond CMCT's control. Although we believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements expressed or implied will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements expressed or implied herein, the inclusion of such information should not be regarded as a representation by CMCT or any other person that CMCT's objectives and plans will be achieved. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made. CMCT does not undertake to update them to reflect changes that occur after the date they are made, except as may be required by applicable laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250805520412/en/

    For CIM Commercial Trust Corporation

    Media Relations:

    Karen Diehl, Diehl Communications, 310-741-9097

    [email protected]

    or

    Shareholder Relations:

    Steve Altebrando, 646-652-8473

    [email protected]

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $CMCT

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Creative Media & Community Trust Corporation
    $CMCT
    4/11/2024$4.00Neutral
    B. Riley Securities
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    Boston Scientific Corporation
    $BSX
    7/19/2023$59.00Outperform
    Robert W. Baird
    More analyst ratings

    $BSX
    $CMCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP& Grp Pres, MedSurg & APAC Butcher Arthur C exercised 17,313 shares at a strike of $24.81 and sold $1,811,520 worth of shares (17,313 units at $104.63) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    8/4/25 5:43:38 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Ludwig Edward J gifted 500 shares, decreasing direct ownership by 3% to 17,979 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    8/4/25 5:43:41 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael sold $5,231,670 worth of shares (50,000 units at $104.63) and exercised 50,000 shares at a strike of $26.15 (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    8/4/25 5:43:40 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Leadership Updates

    Live Leadership Updates

    View All

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

    BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

    1/6/25 9:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/13/25 4:32:41 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Boston Scientific with a new price target

    Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

    6/16/25 7:46:14 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific upgraded by Needham with a new price target

    Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

    4/16/25 9:01:10 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

    1/10/25 8:51:50 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Creative Media & Community Trust Corporation Reports 2025 Second Quarter Results

    Creative Media & Community Trust Corporation (NASDAQ and TASE: CMCT) ("we", "our", "CMCT", or the "Company") today reported operating results for the three months ended June 30, 2025. First Quarter 2025 Highlights Real Estate Portfolio Same-store office portfolio(2) was 70.1% leased. Executed 47,859 square feet of leases with terms longer than 12 months. In April 2025, closed a $35.5 million variable-rate mortgage on an office property in Austin, Texas, using a portion of the proceeds to repay all outstanding obligations under the 2022 Credit Facility. In July 2025, signed a lease with a tenant for 30,831 square feet at our office property at 3601 S Congress Avenue in Austin

    8/13/25 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    Creative Media & Community Trust Notes Year-to-Date Uptick in Office Leasing Activity Executing 140,000-Square Feet

    Leasing activity represents over 55 percent increase from prior year period Creative Media & Community Trust (NASDAQ:CMCT, TASE: CMCT)) ("CMCT") has executed approximately 140,000 square feet of office leases to date in 2025 with 31 tenants. Notable leases executed in 2025 include: A new approximately 31,000-square-foot lease with a global medical technology company at its Penn Field creative office campus in Austin; A new approximately 12,000-square-foot lease with a medical business in Brentwood, California; and A new approximately 11,000-square-foot lease with a government agency in Echo Park, Los Angeles. Since the fourth quarter of 2024, CMCT has executed approximately

    8/13/25 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    Creative Media & Community Trust Announces Date for its Second Quarter 2025 Earnings Release and Conference Call

    Creative Media & Community Trust (NASDAQ:CMCT, TASE: CMCT)) ("CMCT") announced today that it will report its second quarter 2025 earnings results on Wednesday, August 13, 2025 before the opening of the stock market. A conference call is scheduled for 12:00 p.m. Eastern Time later that day to discuss CMCT's financial results and business. The call will be hosted by Chief Executive Officer David Thompson, Chief Financial Officer Barry Berlin, and Portfolio Oversight Steve Altebrando. Interested parties can listen to the call via the following: WEBCAST: Go to www.creativemediacommunity.com and select the "Investors" tab at least 15 minutes prior to the start time of the call to r

    8/8/25 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    $BSX
    $CMCT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Creative Media & Community Trust Corporation

    PRE 14A - Creative Media & Community Trust Corp (0000908311) (Filer)

    8/15/25 5:08:55 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form 10-Q filed by Creative Media & Community Trust Corporation

    10-Q - Creative Media & Community Trust Corp (0000908311) (Filer)

    8/13/25 8:48:13 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    Creative Media & Community Trust Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Creative Media & Community Trust Corp (0000908311) (Filer)

    8/12/25 9:28:36 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    $BSX
    $CMCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Financials

    Live finance-specific insights

    View All

    Creative Media & Community Trust Corporation Reports 2025 Second Quarter Results

    Creative Media & Community Trust Corporation (NASDAQ and TASE: CMCT) ("we", "our", "CMCT", or the "Company") today reported operating results for the three months ended June 30, 2025. First Quarter 2025 Highlights Real Estate Portfolio Same-store office portfolio(2) was 70.1% leased. Executed 47,859 square feet of leases with terms longer than 12 months. In April 2025, closed a $35.5 million variable-rate mortgage on an office property in Austin, Texas, using a portion of the proceeds to repay all outstanding obligations under the 2022 Credit Facility. In July 2025, signed a lease with a tenant for 30,831 square feet at our office property at 3601 S Congress Avenue in Austin

    8/13/25 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    Creative Media & Community Trust Announces Date for its Second Quarter 2025 Earnings Release and Conference Call

    Creative Media & Community Trust (NASDAQ:CMCT, TASE: CMCT)) ("CMCT") announced today that it will report its second quarter 2025 earnings results on Wednesday, August 13, 2025 before the opening of the stock market. A conference call is scheduled for 12:00 p.m. Eastern Time later that day to discuss CMCT's financial results and business. The call will be hosted by Chief Executive Officer David Thompson, Chief Financial Officer Barry Berlin, and Portfolio Oversight Steve Altebrando. Interested parties can listen to the call via the following: WEBCAST: Go to www.creativemediacommunity.com and select the "Investors" tab at least 15 minutes prior to the start time of the call to r

    8/8/25 8:00:00 AM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    Boston Scientific announces results for second quarter 2025

    MARLBOROUGH, Mass., July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported basis, 21.6 percent on an operational1 basis and 17.4 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.62 a year ago.

    7/23/25 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CMCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Creative Media & Community Trust Corporation

    SC 13D/A - Creative Media & Community Trust Corp (0000908311) (Subject)

    9/27/24 4:26:04 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13D/A filed by Creative Media & Community Trust Corporation (Amendment)

    SC 13D/A - Creative Media & Community Trust Corp (0000908311) (Subject)

    4/15/24 5:16:18 PM ET
    $CMCT
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care